Personal information

Emails & domains

Verified email domains

Other IDs

Scopus Author ID: 24174734400
Loop profile: 1490634

Activities

Collapse all

Employment (4)

Nottingham Trent University: Nottingham, GB

2023-09-01 to present | Associate Professor (Biosciences, School of Science and Technology)
Employment
Source: Self-asserted source
Richard Hulse

Nottingham Trent University: Nottingham, Nottinghamshire, GB

2017-10-01 to present | Senior Lecturer (School of Science and Technology)
Employment
Source: Self-asserted source
Richard Hulse

University of Nottingham: Nottingham, Nottinghamshire, GB

2013-09-01 to 2017-09-30 | Research Fellow (Cancer and Stem Cell Sciences)
Employment
Source: Self-asserted source
Richard Hulse

University of Bristol: Bristol, Bristol, GB

2009-08-01 to 2013-08-31 | Research Assistant (School of Physiology and Pharmacology)
Employment
Source: Self-asserted source
Richard Hulse

Education and qualifications (3)

University of Bristol: Bristol, Bristol, GB

2005-09-01 to 2009-11-01 | PhD (School of Physiology and Pharmacology)
Education
Source: Self-asserted source
Richard Hulse

University of Bristol: Bristol, Bristol, GB

2004-09-01 to 2005-08-01 | Molecular Neuroscience MSc (Clinical Sciences)
Education
Source: Self-asserted source
Richard Hulse

University of Manchester: Manchester, Greater Manchester, GB

2001-09-01 to 2004-08-01 | Biochemistry with Medical Biochemistry BSc (hons) (Faculty of Life Sciences)
Education
Source: Self-asserted source
Richard Hulse

Funding (10)

A brighter future cutting-edge multiphoton imaging at Nottingham

2023-07-31 to 2025-07-30 | Grant
Biotechnology and Biological Sciences Research Council (Swindon, GB)
URL: https://app.dimensions.ai/details/grant/grant.13879990
GRANT_NUMBER: BB/X019241/1
Source: Self-asserted source
Richard Hulse via DimensionsWizard

Determination of the sensory and affective components of hypoxia induced chronic pain.

2022-04 to 2023-03 | Grant
Royal Society (Nottingham, GB)
Source: Self-asserted source
Richard Hulse

Functional significance of hypoxia activated dorsal horn sensory neurons in the maintenance and permanence of type 2 diabetic neuropathic pain

2021-01-10 to 2022-09-30 | Grant
Diabetes UK (London, GB)
URL: https://app.dimensions.ai/details/grant/grant.12948416
GRANT_NUMBER:

20/0006289
Source: Self-asserted source
Richard Hulse via DimensionsWizard

Functional significance of HIF1a activated dorsal horn sensory neurons in the manifestation of type 2 diabetic neuropathic pain

2021 to 2022 | Grant
Diabetes Research and Wellness Foundation (Hampshire, GB)
Source: Self-asserted source
Richard Hulse

Pericyte mediated reduction in spinal cord blood flow in diabetic neuropathic pain

2018-10 to 2021-09 | Award
European Foundation for the Study of Diabetes (Dusseldorf, DE)
Source: Self-asserted source
Richard Hulse

Finding the link between how diabetes damages blood vessels in the spinal cord and long lasting pain – a new route to new treatments for diabetic neuropathic pain

2017-05 to 2019-04 | Grant
Rosetrees Trust (middlesex, GB)
Source: Self-asserted source
Richard Hulse

European Foundation for the Study of Diabetes

2016-05 to 2018-04 | Grant
European Foundation for the Study of Diabetes (Dusseldorf, DE)
Source: Self-asserted source
Richard Hulse

Is vascular endothelial growth factor a possible new treatment target in inflammatory arthritis?

2013-10 to 2017-09 | Grant
Arthritis Research UK (Nottingham, GB)
GRANT_NUMBER:

20400
Source: Self-asserted source
Richard Hulse

East Midlands Light Sheet Fluorescence Microscopy Facility for the Evaluation of Complex Biological Applications

Grant
Biotechnology and Biological Sciences Research Council (Swindon, GB)
Source: Self-asserted source
Richard Hulse

Elucidation of new immunomodulatory pain pathways in young adults with long-term sensory neuronal activation after juvenile cancer treatment

Source: Self-asserted source
Richard Hulse

Peer review (5 reviews for 4 publications/grants)

Review activity for Advanced science. (2)
Review activity for Cellular & Molecular Biology Letters. (1)
Review activity for Heliyon. (1)
Review activity for Neurotherapeutics. (1)
How many people are using ORCID?